Core Viewpoint - The company, KPB Medical-B (02216.HK), has entered into a subscription agreement to issue 105.1 million shares at a price of HKD 3.11 per share, representing a premium of approximately 1.3% over the closing price of HKD 3.07 [1][2] Group 1: Subscription Details - The total number of shares to be issued represents about 19.90% of the company's existing share capital as of the announcement date and approximately 16.60% of the enlarged share capital post-issuance [1] - The subscription is backed by two parties: Shanghai Yingtai Medical Devices Co., Ltd., which is engaged in the manufacturing of cardiovascular interventional medical devices, and Hangzhou Linheng Qingrui Enterprise Management Partnership, focusing on enterprise management and development services [1] Group 2: Financial Implications - The total gross proceeds from the subscription are estimated to be approximately HKD 326.9 million, with net proceeds expected to be around HKD 326.5 million after expenses, translating to a net issue price of about HKD 3.106 per share [2] - The net proceeds are intended to fund potential acquisitions in the medical device industry to expand the product portfolio, thereby strengthening the company's liquidity and financial position [2] - The board believes that the subscription will enhance the equity base of the company, optimize its capital structure, and support sustainable development, aligning with the overall interests of the company and its shareholders [2]